It has been two years since Medigene made its "transformative" acquisition of a small German company called Trianta Immunotherapies. Following a series of recent divestments, Medigene is now a fully immune-oncology focused biotech, and Trianta's former CEO Dolores Schendel – who has been Medigene's CSO since the acquisition - is about to take over from Frank Mathias as Medigene's CEO.
Scrip asked Medigene's outgoing CEO Mathias – as he readies to start a new job as CEO of the contract...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?